IL6 and cancer: MPS1i-treated cancer cells have also been reported to escape immune-mediated clearance (Wang et al., 2021), with another study reporting that cancer cells respond to CIN with IL6-STAT3 signaling (Hong et al., 2022) that protects from CIN-induced cell death, allows cells to adapt to CIN- and aneuploidy-induced stresses, and minimizes interferon-related anti-cancer responses.